Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination （CCOP） chemotherapy in patients with peripheral T-cell lymphomas  

作　　者：Yun FAN Neng-ming LIN Lu-hong LUO Luo FANG Zhi-yu HUANG Hai-feng YU Feng-qin WU 

机构地区：[1]Department of Chemotherapy Center, Zhejiang Cancer Hospital, Hangzhou 310022, China [2]Laboratory of Clinical Pharmacy, Zhejiang Cancer Hospital, Hangzhou 310022, China

出　　处：《Acta Pharmacologica Sinica》2011年第3期408-414,共7页中国药理学报（英文版）

摘　　要：Aim： To investigate the pharmacodynamic and pharmacokinetic parameters of pegylated liposomal doxorubicin （PLD） combined with cyciophosphamide, vincristine, and prednisolone in patients with peripheral T-cell lymphomas （PTCL）. Methods： Seven chemonaive patients and four patients with relapsed peripheral T-cell lymphomas were treated with a CCOP regimen consisting of an intravenous administration of cyclophosphamide （750 mg/m2）, vincristine （1.4 mg/m2）, and PLD （30 mg/m2） on d 1, as well as an oral administration of prednisolone （60 mg/m2） on d 1-5. This regimen was repeated every 3 weeks for six cycles, and the clinical response and toxicity of the regimen were monitored. In addition, the plasma concentration of PLD at different time points was determined before and after treatment. The pharmacokinetics （PKs） software was used to estimate the pharmacokinetic param- eters of PLD. Results： The 11 PTCL patients received 35 treatment cycles. Three of them achieved complete response （CR）, two partial response （PR）, four stable disease （SD）, and two progressive disease （PD）. The overall response rate （ORR） was 45.5%, and the CR rate was 27.3%. In the 7 chemonaive patients, three achieved CR, two PR, one SD, and one PD. The ORR was 71.4%, and CR rate was 42.9%. The median follow-up time was 15 months, but 6 out of 11 patients were dead atthe time of data analysis. The 1-year overall surviva rate was 45.5%, and the median progression-free survival （PFS） rate was 6.5 [95% confidence interval （95% CI） 3.17-19.02] with a survival rate of 11.5 months （95% CI 6.65-16.36）. The main toxicity was myelosuppression. Oral mucositis and hand-foot syndrome seldom occurred. The PLD plasma concentration from nine patients ranged from 1.7036 to 9.2207 mg.L^-1 after administration of the CCOP regimen （0-168 h）. The pharmacokinetic parameters AUC0-∞, CL, t1/2, and Vd were 910.76 mg/L.h, 0.043 L.h^-1.m-2, 68.40 h, and 3.56 L/m2, respectively. Conclusion： The CCOP regAim： To investigate the pharmacodynamic and pharmacokinetic parameters of pegylated liposomal doxorubicin （PLD） combined with cyciophosphamide, vincristine, and prednisolone in patients with peripheral T-cell lymphomas （PTCL）. Methods： Seven chemonaive patients and four patients with relapsed peripheral T-cell lymphomas were treated with a CCOP regimen consisting of an intravenous administration of cyclophosphamide （750 mg/m2）, vincristine （1.4 mg/m2）, and PLD （30 mg/m2） on d 1, as well as an oral administration of prednisolone （60 mg/m2） on d 1-5. This regimen was repeated every 3 weeks for six cycles, and the clinical response and toxicity of the regimen were monitored. In addition, the plasma concentration of PLD at different time points was determined before and after treatment. The pharmacokinetics （PKs） software was used to estimate the pharmacokinetic param- eters of PLD. Results： The 11 PTCL patients received 35 treatment cycles. Three of them achieved complete response （CR）, two partial response （PR）, four stable disease （SD）, and two progressive disease （PD）. The overall response rate （ORR） was 45.5%, and the CR rate was 27.3%. In the 7 chemonaive patients, three achieved CR, two PR, one SD, and one PD. The ORR was 71.4%, and CR rate was 42.9%. The median follow-up time was 15 months, but 6 out of 11 patients were dead atthe time of data analysis. The 1-year overall surviva rate was 45.5%, and the median progression-free survival （PFS） rate was 6.5 [95% confidence interval （95% CI） 3.17-19.02] with a survival rate of 11.5 months （95% CI 6.65-16.36）. The main toxicity was myelosuppression. Oral mucositis and hand-foot syndrome seldom occurred. The PLD plasma concentration from nine patients ranged from 1.7036 to 9.2207 mg.L^-1 after administration of the CCOP regimen （0-168 h）. The pharmacokinetic parameters AUC0-∞, CL, t1/2, and Vd were 910.76 mg/L.h, 0.043 L.h^-1.m-2, 68.40 h, and 3.56 L/m2, respectively. Conclusion： The CCOP reg

关 键 词：pegylated liposomal doxorubicin peripheral T-cell lymphomas PHARMACODYNAMICS PHARMACOKINETICS CYCLOPHOSPHAMIDE VINCRISTINE PREDNISOLONE 

分 类 号：S859.796[农业科学—临床兽医学] Q786[农业科学—兽医学]